Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences pulls the trigger on phase II Covid trial after appointing a contract research group
03:02am, Wednesday, 23'rd Jun 2021
Tiziana Life Sciences PLC (NASDAQTLSA, LON:TILS) said it has signed a deal with contract research group FHI Clinical to carry out a phase II, proof-of-concept study on its nasally-administered antibod
NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics fo
Tiziana Life Sciences appoints head of regulatory affairs
02:47am, Monday, 21'st Jun 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) has appointed a vice-president of regulatory affairs. Dr Kevin Shutz, who has 19 years pharma industry experience, 14 of them in the regulatory field,
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
02:00am, Monday, 21'st Jun 2021
NEW YORK and LONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflamma
TLSA Stock Price Increases Over 7% Pre-Market: Why It Happened
05:07am, Thursday, 17'th Jun 2021
The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 7% pre-market. This is why it happened.
Tiziana Life Sciences seeks UK funding for 'take-home' nasal COVID-19 treatment
03:17am, Thursday, 17'th Jun 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it applied for UK government funding for its nasally administered antibody therapy under a scheme looking for ‘take-home treatments' for suffer
Tiziana Responds to UK Call for Development of Innovative ‘Take Home' Treatments for COVID-19 Disease
02:00am, Thursday, 17'th Jun 2021
NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflamma
Tiziana Life Sciences upbeat on potential for coronavirus treatment
09:05am, Wednesday, 16'th Jun 2021
How it is doing Shares have soared recently on the potential for Tiziana's (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoc
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
02:00am, Wednesday, 02'nd Jun 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION
US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news
11:56am, Friday, 28'th May 2021
Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:28pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:22pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
02:01pm, Thursday, 27'th May 2021
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per A
Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study
06:37am, Wednesday, 26'th May 2021
Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed s
Tiziana Life hails 'major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS
05:39am, Wednesday, 26'th May 2021
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered n
